학술논문

A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab
Document Type
Journal
Source
CANCER RESEARCH; JUL 2018, 78 13, 2p. Supplement: S
Subject
Language
English
ISSN
15387445